NCT07817251ClinicalTrials.gov
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes
In brief
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…
Phase 3210 participants sought40 sites1 country
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07817251Open this record at ClinicalTrials.govSynced 2 months ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 210 participants (target), run at 40 sites.
How this score is built
- Enrolment22/40
210 participants (target)
- Site count19/25
40 sites
- Country count0/15
Single country
- Planned duration4/10
Planned over about 10 months
- Sponsor scale9/10
Novo Nordisk A/S has led 339 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Conditions
- Diabetes Mellitus, Type 2
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 210 participants sought |
Sponsor and collaborators
- Novo Nordisk A/S Sponsor
Arms and interventions
- CagriSema dose 1EXPERIMENTAL
Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
- CagriSema dose 2EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
- CagriSema dose 3EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
Interventions
- Drug CagriSema
CagriSema will be administered s.c. once weekly.
Outcome measures
Primary outcome
Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
Time frame From baseline (Week 0) to end of treatment (Week 16)
Secondary outcome
Number of TEAEs
Measured as count of events.
Time frame From baseline (Week 0) to end of study (Week 22)
Secondary outcome
Number of TEAEs
Measured as count of events.
Time frame From baseline (Week 0) to Week 8
Secondary outcome
Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)
Measured as count of episodes.
Time frame From baseline (Week 0) to end of study (Week 22)
Secondary outcome
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
Time frame From baseline (Week 0) to end of study (Week 22)
Secondary outcome
Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Measured as count of episodes.
Time frame From baseline (Week 0) to Week 8
Secondary outcome
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
Time frame From baseline (Week 0) to Week 8
Secondary outcome
Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)
Measured as count of participants.
Time frame From baseline (Week 0) to end of treatment (Week 16)
Dates
| Start date | September 16, 2026 (actual) |
|---|---|
| Primary completion | June 9, 2027 (estimated) |
| Completion | July 21, 2027 (estimated) |
| First posted | September 14, 2026 (actual) |
| Last updated | September 30, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | September 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
37 sites are recruiting
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Albuquerque Clinical Trials Inc. | Albuquerque | New Mexico | Recruiting |
| Amarillo Med Spec LLP | Amarillo | Texas | Recruiting |
| Texas Diabetes & Endocrinology | Austin | Texas | Recruiting |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | Recruiting |
| North Texas Endocrine Center | Dallas | Texas | Recruiting |
| Northeast Research Institute | Fleming Island | Florida | Recruiting |
| Diabetes and Thyroid Center of Fort Worth | Fort Worth | Texas | Recruiting |
| Ark Clinical Research | Fountain Valley | California | Recruiting |
| Gilbert Center For Family Medicine | Gilbert | Arizona | Recruiting |
| Thrive Clinical Research Group | Glendora | California | Recruiting |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | Recruiting |
| AGA Clinical Trial | Hialeah | Florida | Recruiting |
| East West Med Res Inst | Honolulu | Hawaii | Recruiting |
| JCCT- Juno NW Houston | Houston | Texas | Recruiting |
| Sante Clinical Research | Kerrville | Texas | Recruiting |
| Scripps Whittier Diabetes Inst | La Jolla | California | Recruiting |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | Recruiting |
| DCOL Ctr for Clin Res | Longview | Texas | Recruiting |
| Downtown LA Res Ctr. Inc. | Los Angeles | California | Recruiting |
| Advanced Medical Research | Maumee | Ohio | Not yet recruiting |
| Adult Medicine of Lake County, Inc | Mt. Dora | Florida | Recruiting |
| Clinical Research Associates | Nashville | Tennessee | Recruiting |
| Tidewater Physicians Multispecialty Group | Newport News | Virginia | Recruiting |
| Alliance for Multispecialty Research | Newton | Kansas | Recruiting |
| North Hills Medical Research Inc | North Richland Hills | Texas | Recruiting |
| Valley Clinical Trials, Inc. | Northridge | California | Recruiting |
| Optimal Research Sites | Orange City | Florida | Recruiting |
| Dream Team Clinical Research | Pomona | California | Recruiting |
| Clinical Trials Research_Sacramento | Sacramento | California | Recruiting |
| J.Lewis Research Inc | Salt Lake City | Utah | Recruiting |
| NE Clin Res of San Antonio | San Antonio | Texas | Not yet recruiting |
| Linda Vista Health Care Ctr | San Diego | California | Recruiting |
| Diabetes & Endo Treatment Spec | Sandy City | Utah | Not yet recruiting |
| Endeavor Health | Skokie | Illinois | Recruiting |
| Chrysalis Clinical Research | St. George | Utah | Recruiting |
| Cotton O'Neil Diabetes & Endocrinology | Topeka | Kansas | Recruiting |
| Chase Medical Research LLC | Waterbury | Connecticut | Recruiting |
| Iowa Diabetes & Endo Res Ctr | West Des Moines | Iowa | Recruiting |
| Metabolic Research Institute Inc | West Palm Beach | Florida | Recruiting |
| Accellacare Wilmington | Wilmington | North Carolina | Recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
- September 30, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- September 30, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING